Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma

Evidence for efficacy of combination treatment is based the results of the CLEAR study
12 Aug 2021
Anticancer agents & Biologic therapy;  Cancer Immunology and Immunotherapy;  Genitourinary cancers

On 10 August 2021, the US Food and Drug Administration (FDA) approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

The efficacy of this combination was investigated in CLEAR (Study 307/KEYNOTE-581; NCT02811861), a multicentre, open-label, randomised phase III study in patients with advanced RCC in the first-line setting. Patients were enrolled regardless of PD-L1 tumour expression status. The efficacy population supporting this approval included patients randomised to lenvatinib plus pembrolizumab (n=355) compared with those randomised to single-agent sunitinib (n=357).

Progression-free survival (PFS), assessed by independent radiologic review according to RECIST v1.1, and overall survival (OS) were the major efficacy endpoints.

Patients receiving pembrolizumab with lenvatinib had a median PFS of 23.9 months (95% confidence interval [CI] 20.8, 27.7) compared with 9.2 months (95% CI 6.0, 11.0) for those receiving sunitinib (hazard ratio [HR] 0.39; 95% CI 0.32, 0.49; p < 0.0001).

Median OS was not reached in either arm (HR 0.66; 95% CI 0.49, 0.88; p = 0.0049).

The objective response rates were 71% (95% CI 66, 76) and 36% (95% CI 31, 41; p < 0.0001); complete response rates were 16% and 4% on the combination and sunitinib arms, respectively.

The most common adverse reactions reported in ≥20% of patients who received lenvatinib and pembrolizumab in clinical studies are fatigue, diarrhoea, musculoskeletal pain, hypothyroidism, hypertension, stomatitis, decreased appetite, rash, nausea, decreased weight, dysphonia, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, haemorrhagic events, vomiting, constipation, hepatotoxicity, headache, and acute kidney injury. Arterial thrombotic events occurred in 5% of patients in CLEAR, including myocardial infarction (3.4%) and cerebrovascular accident (2.3%).

The recommended dosages for patients with advanced RCC are lenvatinib 20 mg orally once daily with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks or 400 mg administered as an intravenous infusion over 30 minutes every 6 weeks up to 2 years, until disease progression or until unacceptable toxicity.

Full prescribing information for Lenvima is available here and for Keytruda here.

This review used the Real-Time Oncology Review pilot programme, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application approximately 1 month ahead of the FDA goal date.

This application was granted priority review and breakthrough therapy designation for this indication.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings